{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:13:38Z","timestamp":1792700018088,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T00:00:00Z","timestamp":1578873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40265-019-01253-3","type":"journal-article","created":{"date-parts":[[2020,1,13]],"date-time":"2020-01-13T01:02:41Z","timestamp":1578877361000},"page":"181-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Apremilast: A Review in Oral Ulcers of Beh\u00e7et\u2019s Disease"],"prefix":"10.1007","volume":"80","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,13]]},"reference":[{"key":"1253_CR1","unstructured":"Mayo Clinic. Behcet\u2019s disease. 2019. https:\/\/www.mayoclinic.org. Accessed 6 Dec 2019."},{"key":"1253_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2019.00665","volume":"10","author":"BN Tong","year":"2019","unstructured":"Tong BN, Liu XL, Xiao J, et al. Immunopathogenesis of Behcet\u2019s disease. Front Immunol. 2019;10:665. https:\/\/doi.org\/10.3389\/fimmu.2019.00665.","journal-title":"Front Immunol."},{"issue":"2","key":"1253_CR3","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.rdc.2013.02.010","volume":"39","author":"G Hatemi","year":"2013","unstructured":"Hatemi G, Yazici Y, Yazici H. Behcet\u2019s syndrome. Rheum Dis Clin N Am. 2013;39(2):245\u201361.","journal-title":"Rheum Dis Clin N Am."},{"issue":"6","key":"1253_CR4","first-page":"808","volume":"77","author":"G Hatemi","year":"2018","unstructured":"Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Ann Rheum Dis. 2018;77(6):808\u201318.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"1253_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.7861\/clinmedicine.17-1-71","volume":"17","author":"JR Nair","year":"2017","unstructured":"Nair JR, Moots RJ. Behcet\u2019s disease. Clin Med. 2017;17(1):71\u20137.","journal-title":"Clin Med."},{"key":"1253_CR6","doi-asserted-by":"publisher","first-page":"2160610","DOI":"10.1155\/2017\/2160610","volume":"2017","author":"F Adeeb","year":"2017","unstructured":"Adeeb F, Stack AG, Fraser AD. Knitting the threads of silk through time: Behcet\u2019s disease\u2014past, present, and future. Int J Rheumatol. 2017;2017:2160610. https:\/\/doi.org\/10.1155\/2017\/2160610.","journal-title":"Int J Rheumatol."},{"issue":"4","key":"1253_CR7","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","volume":"159","author":"PH Schafer","year":"2010","unstructured":"Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842\u201355.","journal-title":"Br J Pharmacol."},{"key":"1253_CR8","unstructured":"Celgene Corporation. Otezla\u00ae (apremilast) tablets, for oral use: US prescribing information. 2019. https:\/\/dailymed.nlm.nih.gov\/. Accessed 6 Dec 2019."},{"key":"1253_CR9","volume-title":"Otezla\u00ae tablets: Japanese prescribing information","author":"Celgene Co., Ltd","year":"2019","unstructured":"Celgene Co., Ltd. Otezla\u00ae tablets: Japanese prescribing information. Tokyo: Celgene co., Ltd; 2019."},{"issue":"9","key":"1253_CR10","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cellsig.2014.05.014","volume":"26","author":"PH Schafer","year":"2014","unstructured":"Schafer PH, Parton A, Capone L, et al. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity. Cell Signal. 2014;26(9):2016\u201329.","journal-title":"Cell Signal."},{"key":"1253_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","volume":"17","author":"M Perez-Aso","year":"2015","unstructured":"Perez-Aso M, Montesinos MC, Mediero A, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. Arthritis Res Ther. 2015;17:249.","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"1253_CR12","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583\u201390.","journal-title":"Biochem Pharmacol."},{"issue":"7","key":"1253_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.cellsig.2016.01.007","volume":"28","author":"PH Schafer","year":"2016","unstructured":"Schafer PH, Truzzi F, Parton A, et al. Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4\/CD271 complex. Cell Signal. 2016;28(7):753\u201363.","journal-title":"Cell Signal."},{"issue":"3","key":"1253_CR14","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1186\/ar3041","volume":"12","author":"FE McCann","year":"2010","unstructured":"McCann FE, Palfreeman AC, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12(3):R107.","journal-title":"Arthritis Res Ther."},{"issue":"8","key":"1253_CR15","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.624","volume":"42","author":"N Mizuki","year":"2010","unstructured":"Mizuki N, Meguro A, Ota M, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet\u2019s disease susceptibility loci. Nat Genet. 2010;42(8):703\u20136.","journal-title":"Nat Genet."},{"issue":"8","key":"1253_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ng.625","volume":"42","author":"EF Remmers","year":"2010","unstructured":"Remmers EF, Cosan F, Kirino Y, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet\u2019s disease. Nat Genet. 2010;42(8):698\u2013702.","journal-title":"Nat Genet."},{"key":"1253_CR17","unstructured":"Maranville J, Medvedeva I, Yang R, et al. Pharmacogenetics and pharmacodynamics of response to apremilast in a phase 3 clinical study in subjects with active Behcet\u2019s disease [abstract\/poster no. 1694]. In: American College of Rheumatology and Association for Rheumatology Health Professionals annual meeting; 2019."},{"issue":"8","key":"1253_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.5414\/CP202555","volume":"54","author":"M Palmisano","year":"2016","unstructured":"Palmisano M, Wu A, Assaf M, et al. The effects of apremilast on the QTc interval in healthy male volunteers: a formal, thorough QT study. Int J Clin Pharmacol Ther. 2016;54(8):613\u201321.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"16","key":"1253_CR19","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Behcet\u2019s syndrome\u2014a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510\u20138.","journal-title":"N Engl J Med."},{"issue":"20","key":"1253_CR20","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381(20):1918\u201328.","journal-title":"N Engl J Med."},{"issue":"Suppl 2","key":"1253_CR21","first-page":"1182","volume":"78","author":"B Atienza-Mateo","year":"2019","unstructured":"Atienza-Mateo B, Martin-Varillas JL, Loricera J, et al. Apremilast in refractory oral and\/or genital ulcers in Behcet\u2019s disease. Multicenter study of 49 cases in clinical practice [abstract no. SAT0215]. Ann Rheum Dis. 2019;78(Suppl 2):1182\u20133.","journal-title":"Ann Rheum Dis."},{"key":"1253_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215437","author":"G Lopalco","year":"2019","unstructured":"Lopalco G, Venerito V, Leccese P, et al. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behcet\u2019s disease [letter]. Ann Rheum Dis. 2019. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215437.","journal-title":"Ann Rheum Dis."},{"key":"1253_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez267","author":"G De Luca","year":"2019","unstructured":"De Luca G, Cariddi A, Campochiaro C, et al. Efficacy and safety of apremilast for Behcet\u2019s syndrome: a real-life single-centre Italian experience. Rheumatology. 2019. https:\/\/doi.org\/10.1093\/rheumatology\/kez267.","journal-title":"Rheumatology."},{"key":"1253_CR24","unstructured":"Hatemi G, Mahr A, Takeno M, et al. Improvements in disease activity and quality of life for up to 64\u00a0weeks in patients with Behcet\u2019s syndrome: results from the RELIEF study [poster no. OP03.04]. In: 28th European Academy of Dermatology and Venereology congress; 2019."},{"key":"1253_CR25","unstructured":"Dobashi H, Tanaka Y, Kono H, et al. Efficacy of apremilast for oral ulcers associated with active Beh\u00e7et\u2019s syndrome over 28\u00a0weeks in a Japanese subgroup: results from a phase III study [poster no. W-72-6]. In: 63rd annual general assembly and scientific meeting of the Japan College of Rheumatology; 2019."},{"issue":"4 Suppl 1","key":"1253_CR26","first-page":"AB78","volume":"81","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Takeno M, et al. Improvements and correlations in oral ulcers, disease activity, and quality of life in Behcet\u2019s syndrome patients treated with apremilast: a phase III randomized, double-blind, placebo-controlled study (RELIEF) [abstract no. 9892]. J Am Acad Dermatol. 2019;81(4 Suppl 1):AB78.","journal-title":"J Am Acad Dermatol."},{"issue":"Suppl 2","key":"1253_CR27","first-page":"148","volume":"78","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Takeno M, et al. Efficacy of apremilast for oral ulcers associated with active Behcet\u2019s syndrome over 64\u00a0weeks: results from a phase III study [abstract no. OP0146 plus oral presentation]. Ann Rheum Dis. 2019;78(Suppl 2):148\u20139.","journal-title":"Ann Rheum Dis."},{"key":"1253_CR28","unstructured":"Takeno M, Tanaka Y, Kono H, et al. Efficacy of apremilast for oral ulcers associated with active Behcet\u2019s syndrome over 64\u00a0weeks: long-term results from the Japanese subgroup in a phase III study [abstract and poster no. 1697]. In: American College of Rheumatology and Association for Rheumatology Professionals annual meeting; 2019."},{"key":"1253_CR29","unstructured":"Hatemi G, Mahr A, Takeno M, et al. Improvements in disease activity and quality of life for up to 64\u00a0weeks in patients with Beh\u00e7et\u2019s syndrome: results from the RELIEF study [oral presentation 0946]. In: American College of Rheumatology\/Association of Rheumatology Health Professionals annual meeting; 2019."},{"key":"1253_CR30","unstructured":"Kono H, Dobashi H, Tanaka Y, et al. Apremilast for Behcet\u2019s syndrome: results from a phase III, randomized, double-blind, placebo-controlled study in a Japanese subgroup [poster no. 13]. In: 18th international conference on Behcet\u2019s disease; 2018."},{"key":"1253_CR31","doi-asserted-by":"publisher","first-page":"871019","DOI":"10.1155\/2012\/871019","volume":"2012","author":"E Alpsoy","year":"2012","unstructured":"Alpsoy E. New evidence-based treatment approach in Behcet\u2019s disease. Pathol Res Int. 2012;2012:871019. https:\/\/doi.org\/10.1155\/2012\/871019.","journal-title":"Pathol Res Int."},{"issue":"4","key":"1253_CR32","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.semarthrit.2018.05.008","volume":"48","author":"P Leccese","year":"2019","unstructured":"Leccese P, Ozguler Y, Christensen R, et al. Management of skin, mucosa and joint involvement of Behcet\u2019s syndrome: a systematic review for update of the EULAR recommendations for the management of Behcet\u2019s syndrome. Semin Arthritis Rheum. 2019;48(4):752\u201362.","journal-title":"Semin Arthritis Rheum."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-019-01253-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-019-01253-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T15:42:57Z","timestamp":1610466177000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-019-01253-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,13]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1253"],"URL":"https:\/\/doi.org\/10.1007\/s40265-019-01253-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,13]]},"assertion":[{"value":"13 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Emma Deeks is a salaried employee of Adis International Ltd\/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}